重新评估肝硬化患者食管静脉曲张内镜套扎术后质子泵抑制剂的作用:系统综述与荟萃分析
汇总未调整分析显示PPI使用与术后出血(OR 0.76; 95%CI 0.62-0.92)和全因死亡率(OR 0.48; 95%CI 0.24-0.97)降低相关,但更严格的分析(调整后观察性数据及RCT数据)均无显著获益。当前证据不足以支持EBL术后常规使用PPI。
要点
- 汇总未调整分析提示PPI与EBL后出血和死亡降低相关,但调整后及RCT数据无显著获益。
- RCT数据中PPI对EBL后溃疡出血无显著影响(RR 0.54; 95%CI 0.25-1.16)。
- 试验序贯分析表明累积RCT证据对于出血结局把握度不足。
核心结论
- 当前证据不足以支持肝硬化患者EBL术后常规使用PPI。
- RCT数据把握度不足且结论不确定,需开展充分把握度的试验。
研究设计与样本
- 系统检索主要数据库至2025年1月,纳入比较肝硬化患者EBL术后PPI使用与否的RCT和观察性研究。
- 采用随机效应荟萃分析,使用限制性最大似然估计,计算风险比(RR)、比值比(OR)或标准化均数差及95%置信区间(CI)。
主要发现
- 汇总未调整分析中,PPI使用与EBL后出血降低相关(OR 0.76; 95%CI 0.62-0.92; I2=29.6%)。
- 汇总未调整分析中,PPI使用与全因死亡率降低相关(OR 0.48; 95%CI 0.24-0.97; I2=0.0%)。
- 调整后观察性数据显示EBL后出血无显著获益(P>0.05)。
- RCT数据显示EBL后出血和全因死亡率均无显著获益(P>0.05)。
- RCT数据显示PPI对EBL后溃疡出血无显著影响(RR 0.54; 95%CI 0.25-1.16; I2=0.0%)。
关键数值与推荐
- PPI使用与EBL后出血:未调整OR 0.76(95%CI 0.62-0.92; I2=29.6%)。
- PPI使用与全因死亡率:未调整OR 0.48(95%CI 0.24-0.97; I2=0.0%)。
- PPI与EBL后溃疡出血:RCT数据RR 0.54(95%CI 0.25-1.16; I2=0.0%)。
临床怎么用
- 不应仅基于现有证据在EBL术后常规处方PPI。
- 临床决策需结合患者个体情况,并关注正在进行的相关RCT结果。
局限性
- 纳入研究包含观察性设计,可能存在混杂偏倚。
- RCT数据把握度不足,尤其对出血结局。
- 未调整分析与调整后分析结果不一致,提示未控制混杂可能影响效应估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The benefit of proton pump inhibitors (PPIs) in improving outcomes after endoscopic band ligation (EBL) of esophageal varices in cirrhosis remains uncertain. We aimed to evaluate whether PPI use reduces bleeding and mortality after EBL compared with nonuse. METHODS: Major databases were systematically searched until January 2025. Randomized clinical trials (RCTs) and observational studies comparing PPI use vs nonuse after EBL of esophageal varices in patients with cirrhosis were included. Random-effects meta-analyses were conducted using restricted maximum likelihood estimation. Risk ratios (RR), odds ratios (ORs), or standardized mean differences with 95% confidence intervals (CIs) were calculated for outcomes. RESULTS: Eleven studies (4 RCTs and 7 observational) comprising 7,459 patients with cirrhosis undergoing EBL were included. In pooled unadjusted analyses, PPI use was associated with reduced post-EBL bleeding (OR 0.76; 95% CI 0.62-0.92; I2 = 29.6%) and all-cause mortality (OR 0.48; 95% CI 0.24-0.97; I2 = 0.0%). More rigorous analyses showed no benefit: adjusted observational data for post-EBL bleeding and RCT data for post-EBL bleeding and all-cause mortality were not significant ( P > 0.05). Similarly, for the mechanistic outcome of post-EBL ulcer bleeding, RCT data showed no statistically significant effect (RR 0.54; 95% CI 0.25-1.16; I2 = 0.0%). Trial sequential analysis confirmed the cumulative RCT evidence for bleeding is underpowered. DISCUSSION: Current evidence is insufficient to support routine PPI use after EBL. RCT data remain underpowered and inconclusive, emphasizing the need for adequately powered trials.
引用
- Moraes BF, Leite GAPD, Leite GAPD, et al. Re-Evaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. PMID: 41118529. doi:10.14309/ajg.0000000000003800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。